The EC has approved the acquisition of Pfizer’s Consumer Health Business by GlaxoSmithKline, conditional upon the global divestment of Pfizer’s topical pain management business carried out under the ThermaCare brand. EC examined the effects of the proposed transaction on competition in the markets where the activities of the companies overlap and was concerned that the acquisition would reduce competition for topical pain management products, possibly resulting in price increases in a number of EEA countries, including Austria, Germany, Ireland, Italy and the Netherlands.

For the press release, click here.